In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Replimune Group (REPL – Research Report), with a price ...
Recent results raise hope of new "broad, pan-tumor platform" like Keytruda. The emerging drugs are bispecific antibodies that ...
Replimune Group, Inc. REPL announced that the FDA has accepted the biologics license application (BLA) for its lead pipeline ...
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Replimune (REPL) to $21 from $17 and keeps a Buy rating on the shares.
During a Case-Based Roundtable® event, Kathryn E. Beckermann, MD, PhD, discussed second-line regimens with event participants ...
Exicure, Inc. , today announced that on January 19, 2025, Exicure Inc. ("the Company") entered into a Share Purchase Agreement with GPCR Therapeutics Inc., a Korean corporation ("GPCR"), pursuant to ...
Pharmac is also consulting on a joint proposal with Medsafe to increase access to ADHD medicines. The consultation is ...
Research analysts at William Blair upped their Q4 2024 earnings estimates for Bristol-Myers Squibb in a report released on Tuesday, January 21st. William Blair analyst M. Phipps now forecasts that the ...
The pharma expects a modest financial headwind this year from changes to Medicare prescription drug benefits under the Inflation Reduction Act.
Trump Asserts a Muscular Vision of Presidential Power on First Day Back In a flurry of executive actions, President Trump revived disputed claims of broad presidential authority from his first ...
An exhibit at the Chicago Cultural Center is coming under fire. It includes a large puppet titled, "US-Israel War Machine." A brush fire erupted amid powerful winds Wednesday afternoon in the ...